Drugs / MSK-TCR5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07638371 | Jun 2026 → Jun 2030 expected | carcinoma, metastatic malignant neoplasm | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSK-TCR5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07638371 ↗ |
| Modality | Cell therapy | “T-cell receptor therapy (MSK-TCR5)” NCT07638371 ↗ |